Does the media prefer VVOS or PSTV?

In the previous week, Plus Therapeutics had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Vivos Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Vivos Therapeutics' score of 0.94 indicating that Plus Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate VVOS or PETV?

Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 525.56%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Vivos Therapeutics is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivos Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is VVOS or PETV more profitable?

Vivos Therapeutics has a net margin of -127.70% compared to PetVivo's net margin of -902.82%. Vivos Therapeutics' return on equity of -2,325.64% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets Vivos Therapeutics -127.70% -2,325.64% -98.12% PetVivo -902.82% -4,813.07% -281.78%

Does the media refer more to VVOS or PETV?

In the previous week, Vivos Therapeutics and Vivos Therapeutics both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.94 beat PetVivo's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive PetVivo 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MLSS or VVOS?

In the previous week, Vivos Therapeutics had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Milestone Scientific. Vivos Therapeutics' average media sentiment score of 0.94 beat Milestone Scientific's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Milestone Scientific 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer NMTC or VVOS?

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for NeuroOne Medical Technologies and 2 mentions for Vivos Therapeutics. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Vivos Therapeutics' score of 0.94 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NeuroOne Medical Technologies 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vivos Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vivos Therapeutics (VVOS) Competitors

$0.45 +0.01 (+3.13%)

Closing price 04:00 PM Eastern

Extended Trading

$0.45 0.00 (-0.13%)

As of 07:26 PM Eastern

Compare

VVOS vs. PSTV, PETV, MLSS, NMTC, and CTSO

Should you buy Vivos Therapeutics stock or one of its competitors? MarketBeat compares Vivos Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vivos Therapeutics include Plus Therapeutics (PSTV), PetVivo (PETV), Milestone Scientific (MLSS), NeuroOne Medical Technologies (NMTC), and Cytosorbents (CTSO). These companies are all part of the "medical equipment" industry.

How does Vivos Therapeutics compare to Plus Therapeutics?

Vivos Therapeutics (NASDAQ:VVOS) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

Vivos Therapeutics has higher revenue and earnings than Plus Therapeutics. Plus Therapeutics is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A
Plus Therapeutics	$5.21M	5.55	-$22.39M	-$2.30	N/A

26.4% of Vivos Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 2.1% of Vivos Therapeutics shares are held by company insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Vivos Therapeutics has a beta of 6.1, suggesting that its stock price is 510% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.38, suggesting that its stock price is 38% more volatile than the broader market.

In the previous week, Plus Therapeutics had 2 more articles in the media than Vivos Therapeutics. MarketBeat recorded 4 mentions for Plus Therapeutics and 2 mentions for Vivos Therapeutics. Plus Therapeutics' average media sentiment score of 0.97 beat Vivos Therapeutics' score of 0.94 indicating that Plus Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vivos Therapeutics has a net margin of -127.70% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Vivos Therapeutics presently has a consensus price target of $2.80, suggesting a potential upside of 525.56%. Plus Therapeutics has a consensus price target of $56.40, suggesting a potential upside of 1,242.86%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

Plus Therapeutics beats Vivos Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to PetVivo?

Vivos Therapeutics (NASDAQ:VVOS) and PetVivo (NASDAQ:PETV) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

PetVivo has lower revenue, but higher earnings than Vivos Therapeutics. PetVivo is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A
PetVivo	$1.05M	29.60	-$10.95M	-$0.38	N/A

In the previous week, Vivos Therapeutics and Vivos Therapeutics both had 2 articles in the media. Vivos Therapeutics' average media sentiment score of 0.94 beat PetVivo's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
PetVivo	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Vivos Therapeutics has a net margin of -127.70% compared to PetVivo's net margin of -902.82%. Vivos Therapeutics' return on equity of -2,325.64% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%
PetVivo	-902.82%	-4,813.07%	-281.78%

Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 525.56%. Given Vivos Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Vivos Therapeutics is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

26.4% of Vivos Therapeutics shares are owned by institutional investors. Comparatively, 24.5% of PetVivo shares are owned by institutional investors. 2.1% of Vivos Therapeutics shares are owned by company insiders. Comparatively, 10.8% of PetVivo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Vivos Therapeutics has a beta of 6.1, indicating that its share price is 510% more volatile than the broader market. Comparatively, PetVivo has a beta of 1.25, indicating that its share price is 25% more volatile than the broader market.

Summary

Vivos Therapeutics beats PetVivo on 11 of the 15 factors compared between the two stocks.

How does Vivos Therapeutics compare to Milestone Scientific?

Milestone Scientific (NYSE:MLSS) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

Milestone Scientific presently has a consensus price target of $1.00, indicating a potential upside of 212.79%. Vivos Therapeutics has a consensus price target of $2.80, indicating a potential upside of 525.56%. Given Vivos Therapeutics' higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than Milestone Scientific.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Scientific	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Vivos Therapeutics had 1 more articles in the media than Milestone Scientific. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Milestone Scientific. Vivos Therapeutics' average media sentiment score of 0.94 beat Milestone Scientific's score of 0.00 indicating that Vivos Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Milestone Scientific	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Milestone Scientific has higher earnings, but lower revenue than Vivos Therapeutics. Milestone Scientific is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Scientific	$8.90M	3.18	-$6.93M	-$0.05	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

Milestone Scientific has a net margin of -52.01% compared to Vivos Therapeutics' net margin of -127.70%. Milestone Scientific's return on equity of -60.26% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Scientific	-52.01%	-60.26%	-40.23%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

5.8% of Milestone Scientific shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 12.5% of Milestone Scientific shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Milestone Scientific has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, meaning that its stock price is 510% more volatile than the broader market.

Summary

Milestone Scientific and Vivos Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

NeuroOne Medical Technologies (NASDAQ:NMTC) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

NeuroOne Medical Technologies presently has a consensus price target of $11.67, indicating a potential upside of 249.30%. Vivos Therapeutics has a consensus price target of $2.80, indicating a potential upside of 525.56%. Given Vivos Therapeutics' higher probable upside, analysts plainly believe Vivos Therapeutics is more favorable than NeuroOne Medical Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroOne Medical Technologies	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

NeuroOne Medical Technologies has a net margin of -68.35% compared to Vivos Therapeutics' net margin of -127.70%. NeuroOne Medical Technologies' return on equity of -99.43% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroOne Medical Technologies	-68.35%	-99.43%	-70.40%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

NeuroOne Medical Technologies has higher earnings, but lower revenue than Vivos Therapeutics. NeuroOne Medical Technologies is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroOne Medical Technologies	$12.10M	2.40	-$3.61M	-$0.85	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

16.1% of NeuroOne Medical Technologies shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 11.8% of NeuroOne Medical Technologies shares are owned by insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NeuroOne Medical Technologies has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, meaning that its stock price is 510% more volatile than the broader market.

In the previous week, NeuroOne Medical Technologies had 1 more articles in the media than Vivos Therapeutics. MarketBeat recorded 3 mentions for NeuroOne Medical Technologies and 2 mentions for Vivos Therapeutics. NeuroOne Medical Technologies' average media sentiment score of 1.27 beat Vivos Therapeutics' score of 0.94 indicating that NeuroOne Medical Technologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroOne Medical Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vivos Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeuroOne Medical Technologies beats Vivos Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Vivos Therapeutics compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and Vivos Therapeutics (NASDAQ:VVOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, risk, valuation, media sentiment and analyst recommendations.

32.9% of Cytosorbents shares are owned by institutional investors. Comparatively, 26.4% of Vivos Therapeutics shares are owned by institutional investors. 7.3% of Cytosorbents shares are owned by company insiders. Comparatively, 2.1% of Vivos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Cytosorbents has a net margin of -31.85% compared to Vivos Therapeutics' net margin of -127.70%. Cytosorbents' return on equity of -235.57% beat Vivos Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-31.85%	-235.57%	-37.88%
Vivos Therapeutics	-127.70%	-2,325.64%	-98.12%

Cytosorbents has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market. Comparatively, Vivos Therapeutics has a beta of 6.1, suggesting that its stock price is 510% more volatile than the broader market.

Cytosorbents currently has a consensus target price of $5.38, indicating a potential upside of 1,384.81%. Vivos Therapeutics has a consensus target price of $2.80, indicating a potential upside of 525.56%. Given Cytosorbents' higher probable upside, research analysts plainly believe Cytosorbents is more favorable than Vivos Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Vivos Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Cytosorbents has higher revenue and earnings than Vivos Therapeutics. Cytosorbents is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.61	-$8.20M	-$0.19	N/A
Vivos Therapeutics	$19.57M	0.32	-$21.17M	-$2.14	N/A

In the previous week, Vivos Therapeutics had 1 more articles in the media than Cytosorbents. MarketBeat recorded 2 mentions for Vivos Therapeutics and 1 mentions for Cytosorbents. Cytosorbents' average media sentiment score of 1.89 beat Vivos Therapeutics' score of 0.94 indicating that Cytosorbents is being referred to more favorably in the media.

Company	Overall Sentiment
Cytosorbents	Very Positive
Vivos Therapeutics	Positive

Summary

Cytosorbents beats Vivos Therapeutics on 11 of the 16 factors compared between the two stocks.

Get Vivos Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VVOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VVOS vs. The Competition

Export

Metric	Vivos Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.03M	$3.02B	$6.71B	$12.23B
Dividend Yield	N/A	1.77%	2.67%	6.10%
P/E Ratio	-0.21	19.27	26.03	24.18
Price / Sales	0.32	333.24	556.48	101.52
Price / Cash	N/A	56.66	46.99	54.37
Price / Book	-2.80	4.21	10.77	6.35
Net Income	-$21.17M	$64.45M	$3.57B	$337.63M
7 Day Performance	-10.48%	2.24%	3.15%	-0.30%
1 Month Performance	-30.79%	1.74%	2.33%	0.36%
1 Year Performance	-86.72%	26.63%	33.42%	26.94%

Vivos Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VVOS Vivos Therapeutics	3.4246 of 5 stars	$0.45 +3.1%	$2.80 +525.6%	-85.8%	$6.03M	$19.57M	N/A	160
PSTV Plus Therapeutics	2.464 of 5 stars	$4.57 -5.8%	$56.40 +1,134.1%	-45.9%	$31.46M	N/A	N/A	20	News Coverage
PETV PetVivo	N/A	$0.85 +6.3%	N/A	+1.3%	$30.96M	$1.05M	N/A	20	News Coverage Upcoming Earnings High Trading Volume
MLSS Milestone Scientific	1.2472 of 5 stars	$0.34 +0.6%	$1.00 +194.1%	-57.0%	$30.07M	$8.90M	N/A	30	News Coverage
NMTC NeuroOne Medical Technologies	2.8164 of 5 stars	$3.25 -2.1%	$11.67 +259.0%	-26.5%	$28.62M	$9.72M	N/A	20	News Coverage Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VVOS) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vivos Therapeutics (VVOS) Competitors

VVOS vs. PSTV, PETV, MLSS, NMTC, and CTSO

How does Vivos Therapeutics compare to Plus Therapeutics?

Summary

How does Vivos Therapeutics compare to PetVivo?

Summary

How does Vivos Therapeutics compare to Milestone Scientific?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Summary

How does Vivos Therapeutics compare to Cytosorbents?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vivos Therapeutics (VVOS) Competitors

VVOS vs. PSTV, PETV, MLSS, NMTC, and CTSO

How does Vivos Therapeutics compare to Plus Therapeutics?

Which has higher valuation and earnings, VVOS or PSTV?

Do insiders and institutionals hold more shares of VVOS or PSTV?

Which has more risk and volatility, VVOS or PSTV?

Does the media prefer VVOS or PSTV?

Is VVOS or PSTV more profitable?

Do analysts rate VVOS or PSTV?

Summary

How does Vivos Therapeutics compare to PetVivo?

Which has preferable valuation & earnings, VVOS or PETV?

Does the media refer more to VVOS or PETV?

Is VVOS or PETV more profitable?

Do analysts rate VVOS or PETV?

Do insiders and institutionals have more ownership in VVOS or PETV?

Which has more volatility & risk, VVOS or PETV?

Summary

How does Vivos Therapeutics compare to Milestone Scientific?

Do analysts prefer MLSS or VVOS?

Does the media prefer MLSS or VVOS?

Which has stronger valuation & earnings, MLSS or VVOS?

Is MLSS or VVOS more profitable?

Do institutionals & insiders believe in MLSS or VVOS?

Which has more risk & volatility, MLSS or VVOS?

Summary

How does Vivos Therapeutics compare to NeuroOne Medical Technologies?

Do analysts prefer NMTC or VVOS?

Is NMTC or VVOS more profitable?

Which has stronger valuation & earnings, NMTC or VVOS?

Do institutionals & insiders believe in NMTC or VVOS?

Which has more risk & volatility, NMTC or VVOS?

Does the media prefer NMTC or VVOS?

Summary

How does Vivos Therapeutics compare to Cytosorbents?

Do insiders & institutionals believe in CTSO or VVOS?

Is CTSO or VVOS more profitable?

Which has more risk and volatility, CTSO or VVOS?

Do analysts recommend CTSO or VVOS?

Which has higher earnings and valuation, CTSO or VVOS?

Does the media prefer CTSO or VVOS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VVOS vs. The Competition

Vivos Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools